Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit Nanotech Investing
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 Nanotech Investing
Sona Nanotech Touts "Superior" Results from Animal Study for Cancer Therapy, Eyes In-human Study Nanotech Investing
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference Nanotech Investing
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer Nanotech Investing
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results Nanotech Investing
